DoorDash Q2 Revenue Jumps 36% as Orders and DashPass Growth Drive Results 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
OpenAI Restricts Astra AI Over Cyberattack Risks 
UOB Q2 Net Profit Rises 10% as Wealth Management Growth Boosts Earnings 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
SoftBank Q1 Profit Beats Forecast as Intel Rally and OpenAI Investments Boost Returns 
Siemens Energy Q3 Profit Beats Forecast as AI-Driven Power Demand Fuels Growth 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
Novo Nordisk Raises 2025 Outlook Despite Wegovy Pill Miss and CagriSema Setback 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Cloudflare Stock Jumps 15% as Earnings Beat Estimates, 2026 Outlook Raised 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
SAN DIEGO and TORONTO, March 08, 2018 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage biotechnology company developing first-in-class agents that target the dysregulated processes and signaling pathways of cancer cells and address unmet medical needs of patients with life-threatening hematologic cancers, will release its financial results for the quarter and year ended December 31, 2017, on Tuesday, March 27, 2018 after the close of the market.
| Conference Call & Webcast: Tuesday, March 27th @ 5:00pm Eastern Time | ||
| Toll-Free: | (844) 882-7834 | |
| International: | (574) 990-9707 | |
| Passcode: | 8873259 | |
| Webcast: | https://edge.media-server.com/m6/p/h526hjyv | |
| Replays available through April 3rd, 2018 | ||
| Toll-Free: | (855) 859 2056 | |
| Replay Passcode: | 8873259 | |
The live conference call can also be accessed through a link on the Investor Relations section of Aptose’s website at ir.aptose.com. Please log onto the webcast at least 10 minutes prior to the start of the call to ensure time for any software downloads that may be required. An archived version of the webcast along with a transcript will be available on the company’s website for 30 days.
The press release, the financial statements and the management’s discussion and analysis for the quarter ended and year ended December 31, 2017 will be available on SEDAR at www.sedar.com and EDGAR at www.sec.gov/edgar.shtml
About Aptose Biosciences
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences
Greg Chow, CFO
647-479-9828
Email: [email protected]
SMP Communications
Susan Pietropaolo
201-923-2049
[email protected]
LifeSci Advisors
Michael Wood
Managing Director
646-597-6983
[email protected]
